Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.
The US pauses use of JNJ-78436735 after six cases of cerebral venous sinus thrombosis.
The link between Astrazeneca’s vaccine and blood clots strengthens, but forecasts show that it was never expected to generate huge sales.
With results of the full primary analysis now out the spotlight falls on a further 14 as yet unadjudicated Covid-19 cases.
AZD1222 could be rehabilitated by US pivotal trial data showing efficacy of 79%, with no worries about blood clots.
Denmark’s suspension of AZD1222 following blood clots heaps even more pressure on Astra’s US study.
Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.